Navigation Links
Aflac Incorporated Announces Third Quarter Results, Declares Fourth Quarter Cash Dividend
Date:10/23/2007

COLUMBUS, Ga., Oct. 23 /PRNewswire-FirstCall/ -- Aflac Incorporated today reported its third quarter results.

Reflecting a weaker yen to the dollar, total revenues rose 5.1% to $3.9 billion during the third quarter of 2007, compared with $3.7 billion in the third quarter of 2006. Net earnings were $420 million, or $.85 per diluted share, compared with $367 million, or $.73 per share, a year ago. Net earnings included realized investment gains of $1 million, or nil per diluted share, compared with $7 million, or $.01 per diluted share in the third quarter of 2006. Net earnings in the third quarter of 2007 also included a gain of $2 million, or nil per diluted share, from the change in fair value of the interest rate component of the cross-currency swaps related to the company's senior notes, as required by SFAS 133. In the third quarter of 2006, the impact from SFAS 133 reduced net earnings by $3 million, or nil per diluted share.

We believe that an analysis of operating earnings, a non-GAAP financial measure, is vitally important to an understanding of Aflac's underlying profitability drivers. We define operating earnings as the profits we derive from our operations before realized investment gains and losses, the impact from SFAS 133, and nonrecurring items. Management uses operating earnings to evaluate the financial performance of Aflac's insurance operations because realized gains and losses, the impact from SFAS 133, and nonrecurring items tend to be driven by general economic conditions and events, and therefore may obscure the underlying fundamentals and trends in Aflac's insurance operations.

Furthermore, because a significant portion of our business is in Japan, where our functional currency is the Japanese yen, we believe it is equally important to understand the impact on operating earnings from translating yen into dollars. We translate Aflac Japan's yen-denominated income statement from yen into dollars using an average exchange
'/>"/>

SOURCE Aflac Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine news :

1. PM announces a new health care order for India
2. Ramdoss Announces Introduction of RCH-II
3. Britain Announces Third Transfusion Related Mad Cow Case
4. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
5. Tibet Announces the Dalai Lama’s Tour of South Americ
6. NHS announces further Cost cutting Measures
7. Indian PM Announces Of Setting Up India Study Center At Tashkent
8. PowderMed Announces Needle-Less Flu Vaccine
9. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
10. Australian Government Announces Survey To Tackle Childhood Obesity
11. New Zealand Announces 10-year Plan For Betterment Of Mental Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/10/2008)...ng point for behavior change, DES MOINES, Iowa, O...,Americans (51 percent) believe there are good thi...r changes are needed, according to the 2008,EBRI H...oday by the,Employee Benefit Research Institute an...derwritten by the Principal Financial Group(R)., ...
(Date:10/10/2008)...dentialing Center (ANCC) has designated Geisinger ...s came via a conference call to hospital administr...and applause., GMC joins an elite group of only 1...n the United States that have achieved Magnet stat...s recognition., "Achieving Magnet designation is ...
(Date:10/10/2008)... blame , , FRIDAY, Oct. 10 (HealthDay Ne...ve diabetes, being depressed was associated with a..., Publishing in the October issue of the Journal...he University of Washington tracked 10,704 Medicar...d diabetes and were enrolled in a disease manageme...
(Date:10/10/2008)...llence in the implementation of electronic health ...agement Systems Society (HIMSS) announces the reci...onal, Ambulatory and Community Health Organization...L (PRWEB) October 10, 2008 -- Honoring excellence ... (EHRs), the Healthcare Information and Managemen...
Breaking Medicine News(10 mins):Health News:Video: Just What the Doctor Ordered: Survey Shows Americans Adopting Healthier Lifestyles 2Health News:Video: Just What the Doctor Ordered: Survey Shows Americans Adopting Healthier Lifestyles 3Health News:Geisinger Medical Center earns prestigious Magnet designation 2Health News:Older Diabetics With Depression Face Higher Death Rate 2Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 2Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 3Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 4Health News:2008 HIMSS Davies Awards: Nation's Outstanding Healthcare Organizations Recognized 5
...ong Kong experts concluded that there is a genetic...at SARS is transmitted to human beings through// c...e Information Times newspaper on Thursday. The r...et cats, by the Center for Disease Control and Pro...
... adolescents are enjoying the health and social be...ny observers have noted problems related to// over...le sport medicine physicians have seen alarming in...es. The November/December issue of the Clinical Jo...
...n funds to the tune of SFr25 million ($20 million)... Technology in Lausanne to invest in the creation ... the brain. The joint venture, envisaged for five...er in children. Also research to lessen the impact...
...cials have banned the sale of turbot after they de...//at several of Beijing’s fish markets, reports th... Cao Jilin from Europe in 1992. Due to low resist...medicinal supplements, which sometime leave harmfu...
Other Medicine News:Health News:Kids in Sport—Great for Fitness, but Concern About Injurie 2Health News:Kids in Sport—Great for Fitness, but Concern About Injurie 3
(Date:10/10/2008)...tment with Kogenate FS Reduces the,Risk of Joint D...Existing,Joint Damage, BERKELEY, Calif., Oct. 10 ...ay that the U.S. Food and Drug Administration (FDA...) FS Antihemophilic Factor,(Recombinant) to reduce...f,joint damage in patients aged 0-16 years with se...
(Date:10/9/2008)...e need to protect the eyesight of,older people, N...people worldwide who,are blind, 80 percent are ove...oided their blindness if they had been properly di...Release, go to:, http://www.prnewswire.com/mnr/orb... products and equipment, is,partnering with nonpro...
(Date:10/8/2008)...e-USNewswire/ -- The facts are,overwhelming. Every...-Saharan Africa. More than 35,000,000 women, child...ed of AIDS. The Foundation for Hospices,in Sub-Sah...ir families,find compassion and relief from suffer...ing initiative links African hospices and palliati...
(Date:10/8/2008)...ts Expand Testing Using Cellular ... Oct. 8 /- Wild Blueberry antioxidant...ts from a new study,showing Wild Blueberries outpe...e apples, bananas, red grapes and strawberries in ...tivity (CAA) assay. New research,published in the ...
Breaking Medicine Technology:FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 2FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 3FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 4FDA Approves Bayer HealthCare's Kogenate(R) FS Treatment for Routine Prophylaxis in Children with Hemophilia A 5ORBIS and Alcon Call Attention to the Aging Eye 2ORBIS and Alcon Call Attention to the Aging Eye 3In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 2In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 3In celebration of World Hospice and Palliative Care Day, FHSSA Announces Seven New Partnerships Between U.S. Organizations and African Hospices 4Wild Blueberries Take Top Spot in New Antioxidant Research Study 2Wild Blueberries Take Top Spot in New Antioxidant Research Study 3ROXRO PHARMA Announces Positive Clinical Proof of Concept Results for Novel Intranasal Migraine Treatment 1909 1ROXRO PHARMA Announces Positive Clinical Proof of Concept Results for Novel Intranasal Migraine Treatment 1909 2ROXRO PHARMA Announces Positive Clinical Proof of Concept Results for Novel Intranasal Migraine Treatment 1909 3Exelixis Announces May 6 Webcast of Its First Quarter 2008 Financial Results and Business Update Conference Call 4896 1Story of Womans Courage and Medical Innovation Top Choice for Readers 17825 1Story of Womans Courage and Medical Innovation Top Choice for Readers 17825 2Kaiser Permanente Study Finds Diabetes Doubling Before Motherhood 4894 1Kaiser Permanente Study Finds Diabetes Doubling Before Motherhood 4894 2Kaiser Permanente Study Finds Diabetes Doubling Before Motherhood 4894 3Kaiser Permanente Study Finds Diabetes Doubling Before Motherhood 4894 4
...un 7, 2007 - Clinical results from a,Phase II stud...dache Society (AHS) annual meeting showed that MK-...ted peptide (CGRP),receptor antagonist, significan...dosing compared to placebo, and the relief was,sus...l tolerated in,the study. Responses specific to ot...
...ndpoints for Both Efficacy and Safety, LEXINGTON, ...evus Pharmaceuticals, Inc. today announced final r...r NEBIDO (testosterone,undecanoate), a long- actin...t for the treatment of male hypogonadism which the...ermany. The data,from the recently completed 48-we...
Other Medicine Technology:Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 2Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 3Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 4Merck's Investigational Migraine Treatment MK-0974 Significantly,Improved Migraine Pain on Several Efficacy Measures in a Phase II,Study 5Indevus Reports Positive Data From Phase III NEBIDO Trial 2Indevus Reports Positive Data From Phase III NEBIDO Trial 3Indevus Reports Positive Data From Phase III NEBIDO Trial 4Indevus Reports Positive Data From Phase III NEBIDO Trial 5Indevus Reports Positive Data From Phase III NEBIDO Trial 6
...ed on the competition principle and the microplate...n the sample and a fixed amount of DHEA-S conjugat...nding sites of a polyclonal DHEA-S antiserum coate...crotiterplate is washed to stop the competition re...
EL-RF-IgM is high sensitivity quantitative rheumatoid factor IgM.
Latex agglutination test for the qualitative and semiquantitative determination of rheumatoid factor in serum.
Equipped with the SYNCHRON CX4 PRO, which includes many of today's most advanced and automated technologies, your laboratory can improve its specialty testing process dramatically. The SYNCHRON CX4 P
Medicine Products: